Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Can Better Biomarkers Reduce Drug Failure?

12 November 2026 · By · Wire by Fusion42

Published

12 November 2026

Topic

opportunities

◆ Sectors

BiotechDiagnosticsDigital Health

◆ Source

Read at themedicinemaker.com →

◆ Verified

Fusion42 · 12 November 2026 · Fusion42 review

Innovations in biomarker technology and continuous patient monitoring using digital health tools and liquid biopsies are poised to make drug development more precise and potentially reduce costly drug failure rates.

This Wire brief sits within Fusion42's coverage of Biotech, Diagnostics and Digital Health.

◆ ◆ The Wire takeaway

You can now rely on advanced biomarker patterns and continuous monitoring to target patient groups more sharply in trials and cut development waste. Drug developers must act fast on digital biomarkers to secure faster, cheaper market access.

◆ Coverage

1 source · 12 Nov 2026

◆ Related on Wire

◆ Topics

BiotechDiagnosticsDigital Healthbiomarkersdrug-failureprecision-medicineclinical-trialsdigital-health